Clinical Trial Update: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating XL092 in combination with nivolumab versus sunitinib in advanced or metastatic non-clear cell renal cell carcinoma; the trial is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)
• XL092
• nivolumab (nivolumab)

Snippet

Sponsor: Exelixis | Conditions: Non-Clear Cell Renal Cell Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING